Development of immunotherapy and virotherapy against ATL
Project/Area Number |
21590504
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Virology
|
Research Institution | Hokkaido University |
Principal Investigator |
OHASHI Takashi 北海道大学, 遺伝子病制御研究所, 准教授 (10282774)
|
Project Period (FY) |
2009 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | HTLV-I / 成人T細胞白血病 / 動物モデル / 免疫治療 / ウイルス療法 / MHC-I / Single chain trimer / ATL / CTL / Tax / Epitope / Vaccinia |
Research Abstract |
The potential for novel therapies against Human T-cell leukemia virus type I (HTLV-I) induced-adult T-cell leukemia (ATL) has been assessed in a rat model of HTLV-I infection. The results indicate that the single chain trimer (SCT) of MHC-I linked to HTLV-I epitope peptide is able to induce HTLV-I-specific cytotoxic responses and that LC16m8Δ, a highly attenuated vaccinia strain, has an ability to lyse HTLV-I-infected T cells. These results should be useful for further verifying the strategies to fight against HTLV-I.
|
Report
(4 results)
Research Products
(18 results)